ESR1 and breast carcinoma: These 43 genes were defined as our IRFMS, and their names and expression in parental, treated, and resistant cells are shown in Figure 3A. Notably, our IRFMS shows considerable, but not complete, overlap with the genes observed in ER+ breast cancer cells and tumors that have become resistant to other therapies reported by others (Figure 3B).